Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.78 |
| ▸ | MGAM | O43451 | 1/20 | 0.69 |
| ▸ | MAOA | P21397 | 1/20 | 0.69 |
| ▸ | MAOB | P27338 | 1/20 | 0.69 |
| ▸ | XDH | P47989 | 1/20 | 0.69 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.67 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.67 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.67 |
| ▸ | AKT1 | P31749 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.64 |
| ▸ | RELA | Q04206 | 3/20 | 0.64 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | SRC | P12931 | 1/20 | 0.64 |
| ▸ | CDK2 | P24941 | 1/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Licoagrochalcone A SCHEMBL30384736 | 1.00 | PTPN1 (1.00) | PTPN1CYP19A1MGAMMAOAMAOB | |
| Licoagrochalcone A SCHEMBL632908 | 1.00 | PTPN1 (1.00) | PTPN1CYP19A1MGAMMAOAMAOB | |
| SCHEMBL25196627 | 0.90 | PTPN1 (0.81) | PTPN1CYP19A1MGAMMAOAMAOB | |
| Abyssinone Vi SCHEMBL17975268 | 0.89 | PTPN1 (1.00) | PTPN1CYP19A1MGAMMAOAMAOB | |
| SCHEMBL3307176 | 0.89 | PTPN1 (0.79) | PTPN1CYP19A1MGAMMAOAMAOB | |
| SCHEMBL3307174 | 0.89 | PTPN1 (0.79) | PTPN1CYP19A1MGAMMAOAMAOB | |
| SCHEMBL30383478 | 0.89 | PTPN1 (0.79) | PTPN1CYP19A1MGAMMAOAMAOB | |
| Stipulin SCHEMBL633709 | 0.88 | PTPN1 (0.88) | PTPN1CYP19A1MGAMMAOAMAOB | |
| Stipulin SCHEMBL29435847 | 0.88 | PTPN1 (0.88) | PTPN1CYP19A1MGAMMAOAMAOB | |
| Stipulin SCHEMBL633710 | 0.88 | PTPN1 (0.88) | PTPN1CYP19A1MGAMMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20240000841-A1 | LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM | ST ANNA KINDERKREBSFORSCHUNG (AT) | 2024-01-04 | — | — | US | disclosed |
| US-11844813-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2023-12-19 | — | — | US | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2022-02-10 | — | — | US | disclosed |
| US-20210386781-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | UNIVERSITÄT FÜR BODENKULTUR WIEN (AT) | 2021-12-16 | — | — | US | disclosed |
| US-8946287-B2 | Chemotherapeutic flavonoids, and syntheses thereof | PURDUE RESEARCH FOUNDATION (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946287-B2 | Chemotherapeutic flavonoids, and syntheses thereof | PURDUE RESEARCH FOUNDATION (US) | 2015-02-03 | — | — | US | disclosed |
| EP-1888174-B1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | JOHNSON & JOHNSON CONSUMER (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20100099755-A1 | CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099755-A1 | CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099755-A1 | CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2010-04-22 | — | — | US | disclosed |
| WO-2008076767-A1 | CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1888174-A1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | Johnson and Johnson Consumer Companies, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006127539-A1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270614-A1 | Use of chalcones for the treatment of viral disorders | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099755-A1 | CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF | NRAS, FAU, DPYD | PTPN1 4272/4885CYP19A1 104/4885MGAM 1014/4885 |
| US-20060270614-A1 | Use of chalcones for the treatment of viral disorders | HAVCR2, HMGB3, EIF2AK2 | PTPN1 2767/4885CYP19A1 1463/4885MGAM 2435/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | PTPN1 1308/4885CYP19A1 270/4885MGAM 2348/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | PTPN1 1520/4885CYP19A1 320/4885MGAM 987/4885 |
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | CARS1, CD74, HAVCR2 | PTPN1 1563/4885CYP19A1 4621/4885MGAM 2470/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | PTPN1 1520/4885CYP19A1 320/4885MGAM 987/4885 |
| US-20210386781-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | CD74, HAVCR2, CD2BP2 | PTPN1 1140/4885CYP19A1 4662/4885MGAM 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.